News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell Signaling Technology, Inc. Announces Joint Commercialization Partnership with Astellas Pharma Inc. (YPH.BE) in Cancer Personalized Medicine


2/23/2011 8:34:05 AM

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. (Astellas) of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics. Under this agreement, CST and Astellas have pooled their respective worldwide intellectual property estates relating to the fusion kinase, EML4-ALK, to enable the commercialization of diagnostic and therapeutic products targeting this cancer enzyme. CST will have the sole rights to exploit these joint intellectual property estates in the field of human medical diagnostics worldwide. Astellas will have the sole rights to exploit these joint intellectual property rights in the field of human therapeutics worldwide.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES